Form 8-K - Current report:
SEC Accession No. 0001213900-23-015546
Filing Date
2023-02-28
Accepted
2023-02-28 17:20:28
Documents
13
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174444-8k_nektartherap.htm   iXBRL 8-K 24219
2 PRESS RELEASE TITLED NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 202 ea174444ex99-1_nektartherap.htm EX-99.1 93961
  Complete submission text file 0001213900-23-015546.txt   302027

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20230228.xsd EX-101.SCH 3257
4 XBRL LABEL FILE nktr-20230228_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE nktr-20230228_pre.xml EX-101.PRE 22379
7 EXTRACTED XBRL INSTANCE DOCUMENT ea174444-8k_nektartherap_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 23687382
SIC: 2834 Pharmaceutical Preparations